Mettler-Toledo International Inc. (MTD) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

  • Hello, everyone. Thank you for joining us and welcome to the Mettler-Toledo third quarter 2026 earnings conference call. (Operator Instructions) I will now hand the conference over to Adam Uhlman, Head of Investor Relations. Please go ahead.

  • Adam Uhlman - Head of Investor Relations

  • Thanks, Jonathan. Good morning, everyone. I appreciate you joining us. On the call with me today is Patrick Kaltenbach, our Chief Executive Officer; and Shawn Vadala, our Chief Financial Officer. Let me cover some administrative matters. This call is being webcast and is available for replay on our website at mt.com.

  • A copy of the press release and the presentation that we'll refer to on today's call is also available on our website. This call will include forward-looking statements within the meaning of the US Securities Act of 1933 and the US Securities Exchange Act of 1934. These statements involve risks, uncertainties and other factors that may cause our actual results, financial condition, performance and achievements to be materially different from those expressed or implied by any forward-looking statements.

  • For a discussion of these risks and uncertainties, please see our recent annual report on Form 10-K and quarterly and recent reports filed with the SEC. The company disclaims any obligation or undertaking to provide updates or revisions to any forward-looking statements except as required by law. On today's call, we will use non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure is provided in the 8-K and is available on our website.

  • Let me now turn the call over to Patrick.

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Thank you, Adam, and good morning, everyone. We appreciate you joining our call today. Last night, we reported our third financial results, the details of which are outlined for you on page 3 of our presentation. We delivered an excellent third quarter, achieving relatively broad-based growth across our portfolio while capitalizing on improving market demand.

  • Performance was particularly strong in Asia and the rest of the world. Improved sales volume and strong execution of our strategic initiatives result in another quarter of robust growth in adjusted EPS. We continue to benefit from investments in recent years that have strengthened our competitive position and prepared us for the growth opportunities we see ahead of us.

  • We have accelerated our innovation, expanded our digital capabilities, further enhanced our spending of sales and marketing excellence program and evolved our global supply chain setup for increased resilience and agility. As market conditions improve we are well positioned to deliver strong financial performance going forward.

  • Let me now turn the call over to Shawn to cover the financial results and our guidance, and I will come back with some additional commentary on the business and our outlook. Shawn?

  • Shawn Vadala - Chief Financial Officer

  • Thanks, Patrick, and good morning, everyone. Sales in the quarter were $1.1 billion, up 6% in US dollars and in local currencies. Organic local currency sales growth was also 6%. On slide number 4, we show local currency sales growth by region. Organic sales increased 3% in the Americas, 2% in Europe and 13% in Asia rest of world, including 13% growth in China.

  • Slide number 5 shows sales growth by region on a year-to-date basis. On slide number 6, we summarize sales growth by product area. Organic sales increased 6% in laboratory, and 6% in industrial, which included 5% growth in core industrial and 8% growth in product inspection. Food retail declined 2% in the quarter. Lastly, service revenue grew 7%. Slide number 7 details sales growth by product area on a year-to-date basis.

  • Let me now move to the rest of the P&L, which is summarized on slide number 8. Gross margin was 59.8% in the quarter, an increase of 60 basis points due to benefits from favorable price realization, lower tariff rates compared to the prior year and volume growth, partially offset by higher material and transportation costs. R&D amounted to $54 million in the quarter and was up 4% on a local currency basis over the prior period.

  • SG&A amounted to $267 million, an 8% increase in local currency over the prior year and includes sales and marketing investments and higher variable compensation, offset in part by cost savings. Adjusted operating profit amounted to $333.5 million in the quarter, up 8% versus the prior year. Adjusted operating margin was 30.5%, an increase of 40 basis points versus the prior year. Adjusted EPS for the quarter was $12.57, a 13% increase over the prior year. On a reported basis in the quarter, EPS was $12.29 as compared to $10.57 in the prior year and a reconciliation to GAAP is located in our press release.

  • That covers the P&L, and let me now comment on adjusted free cash flow, which amounted to $652 million on a year-to-date basis and was negatively impacted by the timing of tax payments, which were $72 million higher than the prior year. Excluding taxes, free cash flow per share increased 7% versus the prior year.

  • I'll now share additional thoughts on our guidance for the fourth quarter and our initial thoughts for 2027. As you review our guidance, please keep in mind the following factors. First, we are encouraged by the relatively broad-based momentum in our business, especially in China and emerging markets.

  • Second, conditions in the Middle East remain volatile and while we have limited exposure to the region, this could impact customer decision-making should conditions significantly change. We are not currently seeing any change in related customer behavior and have not included an escalation of the conflict in our forecast.

  • Third, we are encouraged by the increasing momentum in activity related to onshoring investments While we are -- excuse me, third, while we are encouraged by the increasing momentum in activity related to onshoring investments, we have not assumed this will be meaningful to our 2027 results. And lastly, we are very confident in our ability to execute on our growth and productivity initiatives and believe we are well positioned to gain market share regardless of the macro environment.

  • Now turning to our guidance, for the fourth quarter 2026, our local currency sales growth forecast is approximately 5% and adjusted EPS is forecast to be in the range of $14.84 to $15.04. Which represents a growth rate of 11% to 13%. At recent spot rates, foreign exchange is not expected to significantly impact our results.

  • For the full year 2026, we have increased our local currency sales growth forecast from approximately 4% to 5% to approximately 5%, reflecting organic growth of 4%. Note that our forecast also excludes the impact on sales and cost of sales from tariff refunds.

  • Adjusted EPS is forecast to be in the range of $47.70 to $47.90, which represents a growth rate of 12%. We've also provided our initial guidance for 2027 and based on our assessment of market conditions today, we expect local currency sales to increase approximately 5%. Our outlook reflects continued strength in China and emerging markets, favorable trends in the US and benefits from our spinnaker sales and marketing growth initiatives and robust product portfolio, offset in part by a cautious view in Europe given various macro uncertainties.

  • Adjusted EPS is forecast to be in the range of $52.50 to $53.50, which represents a growth rate of 10% to 12%. At recent spot rates, foreign exchange is estimated to be a 1% headwind to sales growth and neutral to EPS. Some further comments on our 2027 guidance. We expect total amortization. Including purchased intangible amortization to be approximately $76 million.

  • Purchased intangible amortization is excluded from adjusted EPS and is estimated at $27 million on a pre-tax basis or approximately $1.05 per share. Interest expense is forecast at $68 million for the year, other income is estimated at approximately $22 million. We expect our tax rate before discrete items will decline from 19% in 2026 to 18% in 2027. Free cash flow is expected to be approximately $950 million in 2027, which represents 8% growth on a per year basis. Share repurchases are also expected to be $950 million.

  • That's it from my side, and I'll now turn it back to Patrick.

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Thanks, Shawn. Let me start with some comments on our operating businesses, starting with Flag, which had broad-based growth in the quarter across nearly all product areas. In addition to growth in bioprocessing, it was encouraging to see another quarter of strong growth from customers in quality labs where we saw a wide range of analytical instruments and lab balances. While trends in biopharma and biotech research improved, resulting in very strong growth in our liquid handling business.

  • The board story also benefited from growth in hot segments this quarter like semiconductor, battery and GLP-1 among others. Our innovative portfolio resonates well with customers and we have a deep pipeline of new innovations that will reinforce our technology leadership. In process analytics, we launched a new online bioburden analyzer that provides real-time monitoring of microbial contamination, for example, in pharmaceutical water systems. The launch further strengthens our position in critical bioprocess applications.

  • Turning to industrial, core industrial had another quarter of solid growth on top of 10% organic growth in the prior year. Sales growth this quarter was again led by our automation and digitalization solutions. We have maintained a static cadence of new product introductions in recent years and further expanded our portfolio recently by introducing the ACT305 weighing transmitter, which is a high-performance device designed for fast, accurate transmission of weigh data and status to control systems, enabling enhanced process control.

  • It is easy to use, quick to commission and integrates seamlessly into industrial environments for filling and dosing, check weighing and other applications. Moving on to product inspection, we had a very good quarter with organic growth of 8% with strong results across the portfolio. Our mid-market strategy is working well on helping us target growth opportunities within growth segments of the food manufacturing market.

  • We have also further expanded our portfolio of high-end solutions to help our customers tackle hard-to-detect physical contamination. We also introduced AI-enabled image recognition software for our X-ray systems, improving contamination detection while reducing false rejects for customers.

  • Finally, food retail sales declined slightly due to the timing of project activity, especially in the Americas. Now let me make some additional comments by geography, starting in the Americas, where sales grew 3% versus 9% organic growth in the prior year. We had strong results across most lab product categories, and it is encouraging to see strengthened demand for products used in research and development applications, especially pipettes.

  • Industrial also had good growth on top of double-digit growth in the prior year with strong product inspection results and strength across some of poor industrial products that enable automation and digitalization. Growth in these areas was offset in part by software sales in food retail and transport and logistics due to timing of project activity.

  • Turning to Europe, growth in Europe was modest but broad-based across the portfolio. While macroeconomic conditions remain subdued, customer activity is good and our team continues to execute well on capturing available growth opportunities.

  • Finally, Asia, rest of world had excellent growth results again this quarter with strong growth across the portfolio. This included 13% growth in China. Which was led by our industrial business and strong results across our laboratory products. Other emerging markets also grew double-digits. That concludes my comments on our Q3 restarts and now let me share with you some additional thoughts on our initial guidance for 2027.

  • I recently came off our annual budget tour meeting with our senior leaders around the world. I came away incredibly encouraged by the energy, optimism and focus I saw throughout the business. What stood out most was the breadth of growth initiatives that are being pursued across the organization. Our teams have a deep pipeline of initiatives to drive growth and enhance profitability and are executing at a high level.

  • Importantly, many of the investments we have made over the past several years are beginning to generate tangible results. We have strengthened our product portfolio, accelerated innovation, deployed new tools across our Spinnaker sales and marketing excellence program and enhanced our digital footprint. We have also invested in a more resilient and agile global supply chain.

  • We remain committed to investing to support future growth and see significant opportunities ahead as replacement demand improves, companies increase investments to support onshoring and supply chain resilience, particularly in the United States, and customers place increased emphasis on automating and digitizing the operations.

  • These trends align exceptionally well with our strategy and provide confidence in our ability to drive growth over the long-term. Our biopharma customers are making substantial investments in artificial intelligence, digitalization and next-generation research capabilities that we expect will accelerate drug discovery and development. We are uniquely positioned to support customers with our broad portfolio of innovative solutions across the entire value chain from research and development all the way through manufacturing.

  • From a regional perspective. We expect solid growth in the United States in 2027 where investments in advanced manufacturing and automation are expected to build as the year progresses. We also expect good growth in China despite multiple comparisons given the strong second-half results in 2026.

  • We are well aligned with the investment priorities in China in life sciences, technology. New materials and clean energy, as well as trends in automation and digitalization. We are also well-positioned globally to capture growth in various hot segments such as semiconductors, advanced materials and batteries, to name a few. We expect to see strong momentum across emerging markets and expect these regions to remain important contributors to our long-term growth strategy.

  • We also expect to translate these growth opportunities into another year of double-digit growth in adjusted EPS through the focused execution of our initiatives. In summary, we delivered an excellent third quarter and are pleased to have increased our full-year outlook.

  • We are entering 2027 with positive momentum across the business as the investments we have made over the past several years are producing results and our growth initiatives remain on track. We remain confident in our ability to continue creating compounding value over the long-term and we look forward to discussing our strategy in greater detail at our investment meeting on Monday.

  • So that concludes our prepared remarks. Operator, I'd now like to open the line to questions.

  • Operator

  • (Operator Instructions)

  • Luke Sergott, Barclays.

  • Luke Sergott - Analyst

  • I just wanted to talk about kind of what you're seeing there in China. I know I appreciate some of the color that you gave, but when I'm thinking about the puts and takes that we're seeing here, and it's starting to recover for the rest of the group pretty strongly. Just kind of dig in from an end market perspective and then what's also embedded within that '27 guidance? Like is there any material improvement in some of the slower parts of the areas?

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Thanks for the question. Of course, we are very pleased with the 30% growth we have seen in China this quarter. Increased Q3 to give you a little bit more flavor also included a strong industrial growth and lab growth. The experts are feeling very good about the momentum in China. Because we are, as I said in the previous remarks, we are really well aligned with the investment priorities in China to invest into the future, building out the pharma portfolio, investment in life sciences and technology in new energy and others, this really fits our portfolio very well.

  • We're also benefiting from the in China for China strategy. We have a strong manufacturing footprint there. We have a strong local sales team and can do also benefit from our global tools like Spinigot to really address the hot markets. There's overall, I would say, a broader-based trend clearly into automation and digitalization in China as well.

  • And given all the updates we have made to our portfolio and innovation we have put in there, we feel really well. Position for the future growth in China. Of course, next year, we face, especially in the second-half, we will face some tougher comps, but we are overall really confident. I hand it over to Shawn to really give you some more details in terms of the growth rates in China we expect.

  • Shawn Vadala - Chief Financial Officer

  • Patrick and I were just in China recently to meet with them and then we also, of course, were on our annual budget tour where we got to meet with all the other colleagues in the region as well as around the world. And we really came back feeling very positive on the region in general. What was nice to see is that the breadth of the growth kind of throughout the portfolio, particularly in China.

  • If you think about earlier in the year, we started to see this momentum building on the industrial side, which we continue to see, but we also saw good results in lab in the quarter. I think in the quarter, industrial was probably like mid-teens and lab was.

  • Was a high single-digit, very high single-digit in the quarter. And as we kind of like look to Q4, we see that lab growth probably even further improving. And overall, we're thinking mid-teens for Q4 and China in both businesses. For next year, we're a little bit more modest, just mostly because of the comps that we're facing. We're probably thinking more like mid-single-digit in China for the year as we know things in China can always change quickly going in either direction, but we feel really good about what we're seeing the momentum throughout the portfolio, especially in the pharmaceutical side, I think as Patrick mentioned too.

  • Think about next year, that mid-single-digits, probably more like mid to high on the lab side and maybe more low to mid on the industrial side, acknowledging there could be some upside, but we're just a little bit more cautious given the costs.

  • Luke Sergott - Analyst

  • Okay, great. And then I guess just a follow-up there and continuing on the '27 Guide theme, you guys are usually freeing kind of what you're looking for from that could be upside driver or downside drivers. Outside of geography and macro, but I kind of look at when I'm thinking about the upside, you have a pretty large installed base from an instrumentation perspective.

  • And as I think AI kind of hits in the manufacturing sector, that's an unappreciated aspect of it. And I'm just trying to think about the upgrade cycle from an instrumentation perspective. How much of your stuff is cloud agentic ready and I'm sure that's a huge focus for you on innovation, but as I think about some of upside drivers next year, like could a rebirth or restart of an instrument upgrade cycle be one of them?

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Look, guys, I think you're hitting a good point here is that we have invested a lot into our technology and digitalization capabilities over the last years, and you're absolutely right. We have put a lot of emphasis on making sure that our sensors, our instruments really seamlessly plug into the customers. Digital environment. So we provide what I would call across the value chain all the sensors that you need to take the relevant data to either optimize the manufacturing workflow processes or in the environment.

  • Drive automated labs, etc. What is important is that we also provide what I call the mid-layer data infrastructure that connect to our sensors and instruments that then seamlessly integrates into our customers.

  • AI software solutions and everybody uses something else, but it's important that they have a good interface that can connect against with our instruments. And of course, all the newer products that we have out there connect to it. LabX, for example, is a really strong platform that connects to almost the entire fleet of instruments we have in the lab space.

  • And we typically cover 40% of the bench in the QAQC lab, which is also heavily used in R&D, but that drives self-driving labs and. I think those of you who will be here on Monday will be excited about some of the showcases we have here in that direction as well. So yeah, I think we definitely will benefit from the trend of AI and said that prepared portfolio extremely well.

  • Shawn Vadala - Chief Financial Officer

  • Yeah, and just to be clear, Luke, I think you framed it correctly, like as Patrick says, we're really well positioned for these trends. We will talk more about it on our Investor Day on Monday. But it's not like we've built anything meaningful into our guidance for next year. I view it more as upsides.

  • Luke Sergott - Analyst

  • Great. Thanks.

  • Operator

  • Tycho Peterson, Jefferies.

  • Tycho Peterson - Analyst

  • Hey, thanks. Maybe just sticking with the '27 outlook, wondering if you can break down some of the other assumptions by end market and geographies. You obviously hit on China already, but you're seeing a broader recovery here across the board, right? And are there other areas that are lagging that potentially could come back next year? Maybe just do a walk-through by end market and geography, what's baked into that 5%?

  • Shawn Vadala - Chief Financial Officer

  • Yeah, sure. I'll take that one. And so for 2027. I'll start with the division, so for lab, our guidance is mid to high single-digit, so that would be an improvement from what we saw this year kind of like the momentum we saw in the second-half of the year kind of continuing. One of the nice things with lab is if you kind of think about our business, we kind of like serve the different aspects of the customers' workflow or value chain.

  • Earlier in the year, we were seeing good trends in bioprocessing, last quarter it was Q2. Last quarter, we saw things really improving in the QA/QC bench. And then this quarter, we saw better activity in R&D, which was really nice to see like in areas like pipettes. And so we're encouraged as we kind of go into 2027 in lab. And core industrial, we're guiding mid-single-digit for next year, kind of also benefiting from a lot of the favorable trends in automation and digitalization.

  • In product inspection, we're maybe a little bit more cautious, maybe low to mid-single-digit and PI and then in food retailing, we're also a little bit more cautious with low single-digit. In terms of the Americas, we're guiding mid to high single-digit with kind of some of these favorable trends that we see kind of exiting this year in terms of the market. Europe, we're a little bit more cautious in guiding to low single-digit. And then China, we already mentioned mid-single-digit.

  • Tycho Peterson - Analyst

  • Okay, that's helpful. And then industrials come back better, you had accelerating on a tougher comp here. Is any of that receiving help from the chemical recovery or recapturing delayed orders? Maybe just talk about whether there's any sort of timing elements in what you're seeing now versus broader underlying improvement?

  • Shawn Vadala - Chief Financial Officer

  • I'd say certainly chemical is better than it was in Q1, we had that soft start. I'd say out of our core segments, it's still a softer market relative to like pharma was probably the more standout in the quarter, but nothing special here like that market certainly has different. Has had different challenges in the past with higher energy costs. But right now, we're seeing decent activity there, but it's relatively softer compared to the other markets.

  • Tycho Peterson - Analyst

  • I'll leave it at that.

  • Operator

  • Vijay Kumar, Evercore ISI.

  • Vijay Kumar - Equity Analyst

  • Hi, Patrick. Good morning and thank you for taking my question. Hey, maybe a big picture one for you, Patrick. We've heard a lot of people speak about AI lab in the loop. Some of the things that you speak about liquid handling being very strong, process analytics being strong, are these things, products that go into some of these AI lab in the loop end markets? And have you tried to quantify what it means for Matter?

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Vijay, thanks for the question. Look, lab-in-the-loop or self-driving labs, several ways you can call this. I mean, in bioprocessing, I think we benefit most, of course, from our process analytical portfolio. Where the connectivity of the sensors and the digital interfaces these sensors provide to our customers and seams integrating their data systems allow them to optimize their process and that's mainly manufacturing up there with our digital sensors and increase yield. And productivity, et cetera, and also use their own AI solutions to optimize processes and their setup. But it's important that they have the right data points, and this is where our digital sensors play for the role.

  • On the self-driving labs or lab-in-the-looper approach, I point them more to, let's say, the late-stage or on these sides, whether it's in the pharmaceutical industry or in areas like batteries and other areas where we see these. Labs applying our instrumentation of solutions together with robots that we serve our instruments that could then control together with all ABEX solutions to control the entire workflow and then do self-optimizing experiments. We have, again, this in several accounts already. There's quite a lot of interest in these solutions.

  • And the importance there is also is connectivity. To the AI-driven approach that customers use on their side. Again, everybody has a different model, but the importance is that they have the right data aggregation layer that they provide, for example, with FlapX, they can plug into and then run fully automated experiments and refer to then experiment design and optimization. But it's still, I would say it's still early innings, but we see really strong interest and for those of you who will be here on Mondays, you will see a practical thought of that as well.

  • Vijay Kumar - Equity Analyst

  • Understood. That's helpful. Shawn, maybe one for you on the Q4 guidance assumptions, 5%. It comes get easier. Why. You just did 6%. Why is organic going to slow down in Q4? Maybe if you could just talk about what is pricing in 3Q in Q4 assumptions and why Q4 stepping down, that would be helpful.

  • Shawn Vadala - Chief Financial Officer

  • Yeah, sure, Vijay. So maybe I'll start with the pricing assumption. So in pricing in Q3, it was just over 2.5% and we expect to be in that 2.5% range also in Q4. Probably the biggest difference in Q4 versus Q3 is if you like on one hand, I kind of see the lab getting that mid to high single-digit. Industrial probably being high single-digit, but then maybe going the other way, you see retail down mid-single-digit.

  • And as a reminder, retail was up like I think 19% in Q4 of last year. So it's just lapping a really big comp. And as that business can tend to be lumpy based upon customer activity. And then we're also a little bit more cautious on our product inspection business. I mean, PI has had a very good year-to-date, had a strong quarter, but it's probably going to be more flattish in the fourth quarter.

  • And it's just probably if you look at the comp there for last year and then the year before, I think it grew organically double-digit last year in Q4 and double-digit the year before. So we're just kind of lapping some difficult comps there on a stacked basis. But just more customer activity. We're actually competing really well and the product portfolio looks great. We have some introducing new products as well that you'll see it here on Monday as well too.

  • Operator

  • Dan Arias, Stifel.

  • Daniel Arias - Analyst

  • Good morning, guys. Thank you. Shawn, low singles for Europe. Can you just maybe talk a little bit about what we should expect out of labs specifically in Europe as we look to the end of the year here and then into next year? That's been an area that's soft. It sounded like you felt better about things like bioprocess at least earlier in the year. So how might that translate. You assuming just sort of similar activity overall in European lab or might there be an acceleration trend that we can look forward to?

  • Shawn Vadala - Chief Financial Officer

  • Yeah, so for Europe, I mean, we feel like our team continues to execute really well in a more challenging environment. If you think about all the different topics in the world, Europe is probably a little bit more under pressure for different reasons, whether it be energy costs or whether it's like how some of these. Trade disputes are playing out. If you think about the pharmaceutical industry, certainly, we see a lot more activity outside of Europe than we see inside of Europe.

  • But nonetheless, we still feel like within that low single-digit, it's probably about the lab business is probably still in that kind of mid single-digit kind of a range. In terms of the fourth quarter and with the other businesses being a little bit more cautious and a little bit more exposed to the macro.

  • As we kind of look forward to next year, I mean, of course, we are only sitting on about 1.5 months of backlog at any point in time, but just looking at the different regions, this is the one area that we have probably a little bit of a closer eye on kind of going into next year.

  • Daniel Arias - Analyst

  • And then, Patrick, maybe as a follow-up to Vijay's question there. You guys have been talking about automation and digitalization for a while now, certainly before the AI discussion became what it is today. Is that tangibly accelerating as a growth driver? I mean, is that something that you think will mean more to the P&L next year than this year? And maybe that's what you were saying this question, I just need to hear it again. But I'm just curious about how much more you're seeing that kind of falls into that camp versus prior periods and future periods.

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Clearly, as the portfolio is shifting more in a directional, we see a lot of interest shifting more in the direction that you can call a broader digitalization and automation, but behind it, of course, is a lot of also opportunities as customer now drive leveraging AI. And I think we are exceptionally well positioned because we provide an.

  • The instruments and the terminals to connect to these sensors and instruments and software to connect the instruments and empower them to drive these AI-based solutions. This is still a bit early innings, but we see really good interest in this area and really good engagements with customers across the board, whether it's in pharma, in drug.

  • Discovery areas where they try to drive optimized experimentation, whether it's set in, for example, in the battery segment when you think about. Things like electrolyte composition optimization for different battery types that they really have these labs and these automated setup running around the clock to optimize the chemical or the chemistry that they need for the batteries, etc. This is very exciting to see this, but again, it's.

  • What customers are looking for is really an open environment and a data aggregation layer that they can plug into and drive then their experiments using their own AI approaches, the different ones customers use. I think we are really well positioned there with our digital sensors, with our analytical instruments that we have and the connection layers of software and terminals that customers need to do that.

  • Operator

  • Jack Meehan, Operon Research.

  • Jack Meehan - Equity Analyst

  • Thank you. Good morning, guys. I wanted to ask about the 2027 guide. If you look at the 5% local currency growth, can you just talk about like a few of the factors like price versus volume, how you're thinking about spinnaker share gain versus market growth? And then are you assuming any recovery in the replacement cycle or could that be upside?

  • Shawn Vadala - Chief Financial Officer

  • Hey, Jack, I'll start if Patrick wants to add some color as well. So in terms of the 5% between volume and price, we expect to do just over 2% next year on price, kind of our typical baseline is about 2%, we'll a little bit, we'll do a little bit more than that just given some of the pricing actions we did. Mid-year this year. And of course, we'll continue to evaluate that as we go through next year based upon the inflationary environment. So that puts the volume in the 3%-ish kind of a range.

  • In terms of replacement cycle, I feel like it's always difficult to tell like how much of the things are replacement, but certainly if we look at some of the categories that lend themselves to replace them, we've seen really good activity like in the analytical instrument category now for at least a couple of quarters in a row and so that's very encouraging, same with lab balances.

  • And so right now, we kind of expect what we're seeing to continue into next year. We haven't necessarily built in an acceleration from where we are. We'll talk a little bit more about this at the Investor Day on Monday, but we see this to be certainly a broader theme kind of going forward in terms of exactly how things play out with replacement kind of given the significant sales we had back in '21 and '22 and how.

  • That can play out with the life of our products. And then in terms of market share or market, we don't have like, of course, a perfect view on what the market growth would be just given the breadth of our portfolio, but we certainly feel very good about our ability to gain just a little bit of share each year through our Spinnaker program. And we spent a lot of time this past week with our executive team and the Board just kind of going through a lot of the different things that we're doing. And the program just continues to increase with sophistication, and we'll actually share a little bit of that on Monday as well too.

  • Jack Meehan - Equity Analyst

  • Great. Looking forward to it. Just as a follow-up, could you -- it would be great to get an update on onshoring, just what visible activity are you seeing, either quotes, project funnel, anything in terms of just trying to get visibility into when revenue might start to manifest?

  • Patrick Kaltenbach - President, Chief Executive Officer

  • To see increasing activity in that regard as we use also, for example, as John mentioned, Spinnaker as a tool to identify investments in these areas very early. We have a really good tool there to sense market activity and then guide our sales force to these activities.

  • As we see. Really investment happening and increasing or some of these investments are the longer-term plans. If a pharmaceutical company plans to build a new facility and then ramp it up over the next couple of years, it takes probably two to five years until we see a big momentum out of that facility versus a simple product expansion of an existing facility. So it's a, I would say, multiple year cycle, but. What we see in terms of leads activity and investment activity and alerts that we're getting from our systems, it's really encouraging here in the United States to and it's definitely linked to reshoring activities.

  • Operator

  • Doug Schenkel, UBS.

  • Douglas Schenkel - Equity Analyst

  • Hey, guys, this is Avery on for Doug. Thanks for taking the question. I guess just to follow-up on reshoring, does the election change how your pharma customers are thinking about the US manufacturing projects and how you're thinking about semis and data center demand?

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Hey, look, I think we don't have a crystal ball here. But I would not expect that it's impacting, especially on data centers, which is, of course, one of the, what we call hot segments for us, but it's really in terms of overall revenue contribution, it's rather low.

  • But it provides great growth opportunities because for those, for example, we provide the solution, for example, to check the cooling systems, like the ultra pure water solutions, or if they use coolants also, to use other sensors like the agents and others to control the cooling systems.

  • I think what's in again, I don't have a crystal ball what this election will do to the build-out and even if it slows down, we still would see this as an exciting opportunity moving forward and again, many of those are still under construction build-out and they're coming into the deal a little bit later when they go really live.

  • Shawn Vadala - Chief Financial Officer

  • A lot of these projects are already started, groundbreaking, committed and then even on the onshoring side, I mean, and just to be clear, both of them was likely they're more they're very much upsized to our guidance, like we didn't really build anything specific for them as we kind of built our guidance for next year. But if you think about even the onshoring topic, this was I think this was something that also started.

  • Really coming out of COVID where companies wanted to have more resilient and agile supply chains and I think most companies were already on that path to have more region-for-region production. And then I think that the trade disputes.

  • And tariffs just kind of accelerated that trend, but I think that that's from what we can see that's very much in motion. The magnitude and timing is always maybe the bigger question and more difficult to be answered with precision, but clearly the activity is increasing and we're seeing that as well too in terms of the projects themselves now in terms of like translating into sales will still take some time, but we're not sitting here today thinking that it's going to change significantly.

  • Douglas Schenkel - Equity Analyst

  • Thanks. And then on the higher material and transportation costs that hit margin in the quarter, I guess like how big was that headwind in Q3 and then how much of that is built into Q4 and the '27 guides?

  • Shawn Vadala - Chief Financial Officer

  • Yeah, I mean like there's, of course, a lot of different things going on in our margin. We certainly factored that into Q4 as well and then also into '27. I feel like the team is monitoring it very closely. I think we do a good job on mitigating these things when they come up. We will continue to look at different mitigation actions as we kind of go into next year and we're kind of like in that mode of just trying to make sure we're prepared to mitigate as it changes, but it's a very dynamic environment for sure.

  • Operator

  • Casey Woodring, JP Morgan.

  • Casey Woodring - Analyst

  • Great. Thank you guys for taking the questions. Maybe first, just on product inspection, sorry, that grew 8% in the quarter. You just talked about flat expectations for 4Q in that business, which sounded like a comp dynamic, but you're guiding the low to mid singles there for '27. So maybe just talk a little bit about the 8% you did in 3Q versus the guide for '27. How conservative is that and just kind of what's embedded there in product inspection?

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Look, Casey, we are really pleased again with the organic growth we have seen this quarter and when we have seen this year, our growth is really a combination of our mid-market strategy, but we also compete very well at the high-end, which has recently introduced also new high-end products, which really differentiates us really well in the market.

  • For Q4, as Shawn mentioned, the growth is expected to slow due to customer projects and then also tough comparisons. So it's also in this business, also the timing of projects always how they play in, but also we're facing really tougher comps moving forward. And that's why we also set our expectation a bit more moderate. I think they're competing extremely well portfolio.

  • But overall, of course, the food market is nothing that we overall expect, really high single-digit, right. For us, it's important that we're competing really well and that we continue to take market share, which we are really seeing very well of our portfolio.

  • Casey Woodring - Analyst

  • Okay, understood. And I think your comments around labs growth this quarter sounded like the consumables business, in particular, the pipettes. Was a nice contributor there. Can you maybe just talk about that was softer several quarters ago, it seems like that's very much back to normal. Maybe just talk about how you're thinking about the consumables focused parts of the lab business in '27?

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Yeah, maybe I saw right there with the pipettes and we are really pleased to see that improving conditions because this segment has been subdued in recent years, we think market conditions have been improving across biopharma and biotech research.

  • But we also want to mention that we are really competing well. We launched new pipettes, new electronic pipette, and also some really nice new PFAS-free tips, low retention tips, we call them, that are really very well received in the market. So we are well positioned as market improve, and that, of course, will also then increase the contribution of the consumers, business overall.

  • Operator

  • Josh Waldman, Cleveland Research.

  • Josh Waldman - Analyst

  • Hey, guys. Thanks for taking my questions. I guess, first, a quick follow-up on the stronger liquid handling. If I recall, this category has a much stronger margin profile. I guess, is that right? And if so, I guess, regardless more broadly, how are you thinking about margins. Both gross margins, op margins for '27? And would you expect mix to be a driver to margin expansion next year, just given some of the strength and kind of new pockets within the portfolio?

  • Shawn Vadala - Chief Financial Officer

  • Yeah, hey, Josh, I'll take that one. So our lab business in general tends to be. Higher than the rest of our business in terms of margins and then within the lab business, certainly our liquid handling business is one of our better margin businesses for sure. As Patrick said, we're very encouraged to see market conditions improve, but also really happy to see some new products being launched, some new innovation that's really well received in the market and that, of course, is the key to sustaining margins in the future.

  • In terms of '27, as we kind of like look at the year with lab being a little bit better versus the other divisions, of course, this implies that we should probably have a little bit of favorable mix within the portfolio. But maybe I'll kind of like walk through things for next year. At the operating margin level, we're probably thinking, of course, this depends on where you are in our range. At the midpoint, it's maybe at operating margin plus 70 basis points to put in an order of magnitude if you're at the high end of the range, it would be about 90 basis points in terms of margin improvement year-over-year.

  • We're a little bit more modest when it comes to the gross. Gross profit margin expansion next year is probably flattish, maybe up slightly. But one of the things we're just a little bit more cautious with two things, one is we are keeping an eye on this inflation, but then the other thing is the tariff rates, right, like we're kind of assuming that the rates go back to the previous IEPA rates next year, we'll see how that plays out, but that's at least how we're kind of positioning ourselves sitting here today.

  • Josh Waldman - Analyst

  • And then, Patrick, you commented on strong core. I guess, any more detail or context you can provide on where you're seeing. Pockets of acceleration or maybe decel within core industrial. And then regarding onshoring, is this something that primarily hits pharma or are you also starting to see onshoring opportunities show up in the more industrial accounts? And then where are these opportunities in the pipeline? Is it already hitting revenue or do you think it's more opportunities that have yet to hit orders and yet to hit revenue?

  • Patrick Kaltenbach - President, Chief Executive Officer

  • Good, great question, Josh. So let me start first with industrial or core industrial. Again, the majority of the growth is seen here as really industrial automation. Our customers are building out automation capabilities that means not only end customers, but also customers like system fabricators and system integrators who build automation solutions for customers, whether it's pharma or other industrial opportunities out there.

  • That's where it's driving the growth there and across the board, we talked about that in China, but we also see that in the U.S. And some of it is also linked, of course, to the reshoring and onshoring activities to the United States because as customers expand to set facilities over here or build new facilities over here, they are looking then to also use our automation solutions coming from industrial.

  • Overall on reshoring and onshoring, as I said, we are excited to see the activity, what we saw in the funnel, there is really good customer engagement there, we see a lot of activity. But it's still really . We see this as increasing momentum that will contribute in the second-half of '27 and the years ahead. There is some revenues, of course, also that we have seen in this quarter, but still very early. I think the majority there is really still to come. I expect this to be a stronger and longer-term way for us, especially in the United States. We have some seen some of it also in, for example, in the emerging markets around China over the last years, and it will continue potentially as well.

  • Josh Waldman - Analyst

  • Got it. Thanks for the detail, guys.

  • Operator

  • Evie Kozlowski, Goldman Sachs.

  • Evie Koslosky - Analyst

  • Great. Thank you for taking my questions. So I think this is the second quarter you've mentioned strength in emerging markets. Maybe just talk through the investments you're making there and then the durability of those trends and then any particular geographies you would specifically call out?

  • Shawn Vadala - Chief Financial Officer

  • Hey, Evie, this is Shawn. I'll take that one. So like as I mentioned earlier, Patrick and I just kind of came off of our annual budget tour and we kind of wrapped up in Asia Pacific and it was just a great way to end the tour because just the number of opportunities and like the enthusiasm, frankly, that we felt from the teams was really encouraging. We've always felt like we have a really great footprint in the region. We've been there for so many years with dedicated direct sales.

  • In a lot of these countries like the various countries within Southeast Asia or India or Korean, etc. And I think that dedicated focus with direct sales. Is a real key differentiator for us and they all benefit from the same program spinnaker that we see worldwide. And I think we've also been incrementally investing in these countries for a while. We have most of them have very specific dedicated strategic growth plans that they review with us on a regular basis. And then frankly, just even coming off this tour, we were.

  • Looking at opportunities for incremental investment going into next year, just given the strength of momentum. So we feel really good. And then when you think about this global footprint of all the emerging markets, including Eastern Europe and Latin America as well, I think emerging markets outside of China are about 17% of our sales. And then China is going to be in that 16% maybe this year probably around 17%. So it's a very.

  • It's a very chunky piece of business, more than a third to maybe a little bit more than a third of our business in these faster growth areas right now. And if you think about these regions, of course, they're the ones benefiting a lot from nearshoring or China+1 strategies or India with a lot of the generics opportunities, et cetera.

  • Evie Koslosky - Analyst

  • Great. That's super helpful. And then on pharma, given the strength there, maybe just walk through biotech versus large pharma and then any particular instruments that are selling into that space that have seen recent strength and then contributions from a broader market improvement versus any new product launches?

  • Shawn Vadala - Chief Financial Officer

  • Yeah, the one thing we saw in the quarter as Miguel started to answer is Biotech had been under a lot more pressure, right, for several quarters in a row and what was nice is that if you think about the one area, we don't have a significant exposure there, but the one area we do is liquid handling and pipettes and we certainly saw improved activity for sure with strong growth in the quarter there, so that was very encouraging.

  • Very encouraging for us to see. And in addition to that, it was kind of like a great one-two punch because as the market was recovering, we also have some new products that we're bringing to the market as well too. So it's hard to say how much of it was market versus product, but clearly, the market conditions have improved. But hey, these new products, they're just being launched, so it's still a little early, but very well received.

  • Patrick Kaltenbach - President, Chief Executive Officer

  • And back to your question, Tony? Back to you, maybe it's a step one sentence. So back to your question regarding the portfolio, it is across the board from all the QA to C into manufacturing. It's not only the sensors that go for example into bioreactors, but it's also industrial weighing applications that we sell in pharma as well. So it's really driving a lot of good contribution for us across portfolio.

  • Operator

  • Michael Polark, Wolfe Research.

  • Mike Polark - Equity Analyst

  • One topic, two-parter, China. If I have the math correct, the original guide for China in '26 was low single-digit growth. I think you're tracking to do something like 9% or 10%. How would you bridge that variance? Is that broad-based upside or is there one or two things that deviated positively from. From your model.

  • And the second part is for the mid-single-digit growth guide for China in '27. I understand it's a volatile geography and your visibility is generally low regarding backlog, so things can swing. But as you reflect on a long history in China, what's a reasonable up-down band versus an initial Mettler forecast for, say, mid-singles? I'd appreciate some perspective on that.

  • Shawn Vadala - Chief Financial Officer

  • So, I mean, when you look at the full year guidance and if you kind of squeeze out, well, if you kind of apply this Q4 guidance that we talked about earlier, we're probably more in the 10% range for China, frankly, for this year. This has been a great year for China, right? Like we saw things starting to gradually improve as every quarter, it started with the industrial business.

  • And now we're seeing it also in the laboratory business. So like it's really nice to see that it's i like the fact that it's also been a little bit more gradual even though it's a lot different than it was at the beginning of the year instead of being very spiky.

  • But at the same time, we've set up for many years, things in China, in particular, can change very quickly more than other regions. And so it's just a little bit what we given that we only have about 1.5 months of backlog at any point in time, that's why we're just a little bit more cautious as we look next year. But clearly, there could be a swing factor going into next year and acknowledging that sitting here today, there's probably looks like there's more upside there than downside.

  • Casey Woodring - Analyst

  • Thanks, Shawn.

  • Operator

  • There are no further questions at this time. I will now turn the call back to Adam for closing remarks.

  • Adam Uhlman - Head of Investor Relations

  • Great. Hey, thanks, Jonathan, and thank you everybody for your excellent questions. If you have any follow-ups, please feel free to reach out to me, and I hope you all have a great weekend.

  • Operator

  • This concludes today's call. Thank you for attending. You may now disconnect.